The Cell Culture Market is expanding steadily as demand grows for biopharmaceutical production, vaccine development, regenerative medicine, and advanced research applications. Increasing investments in biotechnology, rising adoption of cell-based assays, and growing pharmaceutical R&D activities are driving market growth. Technological advancements in cell culture media, bioreactors, and automated systems are further improving scalability and efficiency.…

The convergence of artificial intelligence and bio-manufacturing is reshaping how pharmaceutical companies, biotech firms, and food technology producers

Published in Membranes

Compost scales larger more efficiently than ever with bioreactors instead of compost piles. Zach Wolf demonstrates his farm’s method for creating rich, organic compost.VIDEO TRANSCRIPTZach Wolf: I’m Z...

Abstract. Characterizing CRISPR interference (CRISPRi) phenotypes presents a fundamental temporal challenge: pre-existing overabundance of target proteins

A team of molecular biologists wants you to forget about strawberries and, instead, take "cell jam" for a whirl

The Iowa Nutrient Reduction Strategy calls for a 45% reduction in nitrogen (263 million pounds) to shrink the size of the deadzone in the gulf. In the most recent ILF webinar, Chris Hay poses the question, "What if we estimate nitrogen reduction in pounds?".  By looking at bioreactors' ability to remove nitrogen (N) by pounds we can answer site-level questions. Like, which installations are underperforming?

La première ferme de viande cultivée au monde a ouvert aux Pays-Bas, produisant de la viande en bioréacteur sans élevage ni abattage traditionnel.

Windfall Bio raised $37 million on a simple promise: feed methane to bacteria, harvest the fertilizer, and let farms turn a greenhouse gas into a margin. In April 2026 the company stopped operating. Its bioreactors in Texas are now listed for auction. 🎯 The biology cleared every early test: commercial-scale fermentation, an organic certification, and a 23–34% yield gain over conventional fertilizer. The economics did not. A failed Series B ended a company with 17 institutional backers and no acquirer. The read-across for methane-to-value: a capital-intensity business that has been priced like a biology story. Methane drives a large share of the warming locked in this decade, and agriculture is one of its biggest sources. Methanotrophs, the microbes that eat the gas and excrete nitrogen, sit at the center of a bet that the cheapest way to destroy methane is to sell what it becomes. $37M total capital raised #### Windfall Bio's lifetime funding A $9 million seed in 2023 and a $28 million Series A in 2024, led by Prelude Ventures with Amazon's Climate Pledge Fund. · _AgFunderNews, 2026_ 17,000 L fermentation scale #### Microbe production milestone, January 2025 The company scaled fermentation of its methane-eating microbes to 17,000 liters, enough to make the microbes by the metric ton. · _Waste Today, 2025_ 23–34% yield gain vs. feather meal #### FOUNDATION fertilizer field trial Romaine lettuce yields rose 23–34% over feather meal and matched pricier soy hydrolysates. · _AgFunderNews, 2025_ ## The chemistry was never the bottleneck While the company was scaling steel, the science kept getting cheaper. Three 2026 results show the direction of travel. In Trends in Biotechnology, researchers described engineering a methane-producing archaeon, Methanosarcina acetivorans, to run its metabolism in reverse. The reversal let the organism consume methane instead of emitting it, converting the gas into value-added products. The work sidesteps a long-standing constraint: most methane-eating archaea are hard to culture and hard to engineer, so the field has leaned on a narrow set of aerobic bacteria. A second study in Frontiers in Microbiology enriched a heat-loving methanotroph consortium from ordinary compost. Inside a biofilter, the consortium oxidized methane at roughly 140 milligrams per kilogram of compost per hour without added nutrients, a result that points toward low-cost passive treatment of landfill and composting emissions. A third project, SynYeast at Aston University, is funded through the UK's Horizon Europe guarantee and aims to build methane-based biomanufacturing into yeast. If it holds, methane conversion stops depending on exotic microbes and starts running on the same fermentation equipment used for beer and insulin. A 2026 review in Energy & Environment Nexus catalogued the wider menu: methanotrophic communities converting greenhouse gas into green plastics, animal feed, and fuels. The framing matters. Methane stops being a liability to neutralize and becomes a feedstock with several possible exits. Other work points at passive systems that need no bioreactor at all. A framework published in Trends in Microbiology proposed treating aerated caves, and possibly decommissioned mines, as natural methane biofilters, where surface bacteria oxidize the gas as air circulates through the rock. It is speculative, but it sketches a version of methane removal with almost no steel in it. A third thread works on the supply side of the problem. A 2026 preprint reported that adding gypsum to anaerobic digesters redirects electron donors away from methane production and toward sulfate reduction, cutting emissions before they form. Interventions like that compete with Windfall's model on cost rather than on product. 💡 The common thread: methane conversion is moving toward standard fermentation hardware and away from bespoke organisms. That favors whoever already owns the tanks. ## What $37 million actually bought The company's arc is unusually well documented for a startup that failed, which makes it a case study rather than a eulogy. Josh Silverman co-founded the company in 2022 in San Mateo, California, with Carla Risso and Louis Stenmark. Silverman had already built Calysta, a gas-fermentation company that turns methane into high-protein animal feed. It took the same feedstock and aimed at fertilizer instead. The funding arrived quickly. A $9 million seed in 2023 was followed by a $28 million Series A in April 2024, led by Prelude Ventures, with Amazon's Climate Pledge Fund, Breakthrough Energy Ventures, Bessemer Venture Partners, Mayfield, SOSV, and Global Brain taking part. Seventeen institutional backers in total. The milestones came too. By January 2025 the company had scaled fermentation of its methane-eating microbes to 17,000 liters, enough to produce the microbes by the metric ton. In August 2025 its FOUNDATION fertilizer earned certification from the Organic Materials Review Institute (OMRI), the gatekeeper for organic farming inputs. In October 2025 it broke ground on a demonstration plant in Houston; the roughly 5,000-square-foot facility, a $5 million investment, opened in December with 10 full-time roles. In November, field trials run by Ag Metrics Group showed FOUNDATION lifting Romaine lettuce yields 23–34% over feather meal. Silverman framed the logic plainly that November. "Many people who were turning methane into electricity have turned off their generators because it doesn't make the money anymore," he told AgFunderNews. "We said, can we do something better?" > Many people who were turning methane into electricity have turned off their generators because it doesn't make the money anymore. We said, can we do something better?— Josh Silverman, co-founder and CEO, Windfall Bio The answer turned out to be: maybe not yet. By spring, the company was raising a Series B. The round never closed. The company ceased operations in April 2026, and by late May auctioneer Silicon Valley Disposition was selling off LC/MS/MS systems, HPLC units, freeze dryers, and bench-top bioreactors in San Mateo, plus large-scale bioreactors at the Texas site. No acquirer stepped in for the platform. That is the part that should worry the rest of the sector. The collapse was a cost problem. The fertilizer worked. Making it was expensive, and no patient buyer wanted the machine that made it. As we wrote in August, the moat in gas fermentation is hardware, not the microbe. The structural problems are easy to name. Point-source methane, the kind found at manure lagoons and landfills, is dilute, so capturing it costs more per tonne than the gas is worth as a commodity. On-site bioreactors push capital spending onto the customer, and farms and landfills are not venture-funded. Organic fertilizer competes on price with commodity nitrogen, which is cheap when natural gas is cheap. Carbon credits could bridge the gap, but they depend on registries and policy that shift with elections. Against all that, a startup needs a decade of patient capital. The 2025–2026 funding market offered quarters. ## The next cohort is betting lighter The companies still working in methane-to-value are mostly avoiding Windfall's vertical integration. Instead of owning a farm's bioreactors, they sell a strain, an additive, or a service. C1iN, an Arlington, Virginia company, designs methanotroph strains and fermentation processes and pitches them as inputs for agriculture, ingredients, and materials; it entered an accelerator in April 2026. SynBioBlox, based in Edmonton, is building methane-based synthetic biology for fuels, agricultural additives, and industrial materials. Both are asset-light next to a demo plant. On the feed side, Volta Greentech raised about €1.7 million in early 2026 to launch Lome, a feed additive that suppresses methane-producing microbes in a cow's rumen. Provectus Algae, an Australian synthetic-biology company, is scaling Surf'N'Turf, an algae-based methane-reducing supplement, after a $10.1 million Series A. These products slot into existing farm operations rather than requiring a new industrial facility on site. Calysta, Silverman's earlier company, remains the counter-example that worked. It sells high-protein animal feed made by gas fermentation, treating the feedstock as a route to a premium product rather than a climate obligation. Parameter| Windfall Bio| Calysta| Volta Greentech ---|---|---|--- **Model** | On-site fertilizer bioreactors | Centralized gas fermentation | Feed additive **Product** | Organic fertilizer | Protein feed and petfood | Rumen methane inhibitor **Capital profile** | High: customer-site spending | High: centralized plants | Low: formulated additive **Status** | Ceased operations, April 2026 | Commercial production | Market launch, 2026 _Sources: AgFunderNews; company disclosures, 2026._ ## Signals to track 📊 **Four things to watch** Who buys Windfall's bioreactor assets. An IP or process buyer signals residual value; a pure liquidation signals none. The Series B climate for capital-heavy agrifoodtech through the rest of 2026. Cost per tonne of methane abated at dilute sources, the number that decides whether on-site conversion can beat flaring or a pipeline. Whether additive and licensing models reach commercial volume before the next funding freeze. The collapse will be read as a verdict on methane-eating microbes. It is a verdict on a business model. The microbe ate the methane. The machine that fed it, and the market that was supposed to pay for the fertilizer, are what failed. Investors watching the category should keep the two apart. Exclusive: Waste methane to fertilizer startup Windfall Bio auctions off assets AgFunderNews reported the asset auctions at Windfall's San Mateo headquarters and Texas demonstration plant, and the $37 million the company raised before the Series B that never closed. AgFunderNews The primary account of the wind-down and the clearest source for the company's funding history. Waste methane to fertilizer: Windfall Bio trial shows yield bump in specialty crops Field-trial data showing a 23–34% yield gain over feather meal, plus the clearest statement of the company's commercial reasoning from its co-founder. AgFunderNews Documents that the product worked in the field, which is what makes the shutdown a business failure rather than a science failure. Windfall Bio Shuts Down — Auctioning Off $37M Worth of Bets on Methane-to-Fertilizer A post-mortem framing the collapse as a structural problem for capital-heavy agri-climate ventures: $37 million raised, 17 institutional investors, no viable exit. Saudi FoodTech Independent synthesis that separates the technology's promise from the funding environment that shut it down.